Beijing Bohui Innovation Biotechnology Group Co Ltd

The company's capital structure is characterized by a debt-to-equity ratio of 1.28, indicating a moderate reliance on debt financing. Its liquidity position is assessed as medium, with a current ratio of 0.93, suggesting limited short-term liquidity to cover immediate obligations. The company reported negative operating cash flow of -135.17 million CNY and free cash flow of -264.62 million CNY, reflecting ongoing cash outflows. Profitability metrics show a return on equity of -7.15% and a return on assets of -2.14%, both significantly below the industry median for pharmaceuticals, which typically exceeds 10% ROE and 5% ROA. The company reported a net loss of 91.92 million CNY and an operating loss of 127.71 million CNY, indicating a challenging operating environment. The company's revenue is not segmented by product or geography in the latest financial data, but its exposure is likely concentrated in the Chinese market given its domestic operations and lack of international revenue disclosure. No material geographic diversification is evident from the available data. The company's growth trajectory is uncertain, with no specific revenue growth or decline percentages provided in the outlook. However, the negative operating and net income suggest a lack of current growth momentum. Capital expenditures of -156.92 million CNY indicate ongoing investment in infrastructure or R&D, but the negative sign suggests these are outflows rather than inflows. The company's risk profile includes medium liquidity risk due to its current ratio and negative free cash flow. Dilution risk is assessed as low, with no significant dilution events or share issuance plans disclosed in the latest filings. The company's debt load and negative cash flows are key risk factors that could impact its ability to service obligations or fund operations without external financing. No recent events, such as earnings calls, regulatory filings, or press releases, are disclosed in the available data to provide insight into the company's strategic direction or operational developments.